Plasma cell neoplasms

Diagnostic Histopathology

Volumn 15, Issue 3, 2009, Pages 134-141

  Lin, Pei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

M protein; MGUS; Plasma cell myeloma

Indexed keywords

AMYLOID P COMPONENT; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 6; M PROTEIN;

AMYLOIDOSIS; ARTICLE; BLOOD SMEAR; BONE MARROW BIOPSY; CANCER INCIDENCE; CANCER MORTALITY; CHROMOSOME ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MOLECULAR GENETICS; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PLASMA CELL LEUKEMIA; PLASMACYTOMA; POEMS SYNDROME; PROGNOSIS; PROTEIN ELECTROPHORESIS;

EID: 61749090027     PISSN: 17562317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2009.01.009     Document Type: Article

References (37)

1. Kyle R.A., and Rajkumar S.V. Multiple myeloma. Blood 111 (2008) 2962-2972
2. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121 (2003) 749-757
3. McKenna R., Kyle R., Kuehl W., Grogan T., Harris N., and Coupland R. Plasma cell neoplasms. In: Swerdlow S.H., Elias C., and Harris N.L. (Eds). WHO classifiation of tumours of haematopoietic and lymphoid tissues (2008), IARC, Lyon 200-213
4. Rajkumar S.V., and Greipp P.R. Angiogenesis in multiple myeloma. Br J Haematol 113 (2001) 565
5. Bartl R., Frisch B., Fateh-Moghadam A., Kettner G., Jaeger K., and Sommerfeld W. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol 87 (1987) 342-355
6. Greipp P.R., Leong T., Bennett J.M., et al. Plasmablastic morphology - an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 91 (1998) 2501-2507
7. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 20 (2006) 1467-1473
8. Snozek C.L., Katzmann J.A., Kyle R.A., et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 22 (2008) 1933-1937
9. Dispenzieri A., Kyle R.A., Katzmann J.A., et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111 (2008) 785-789
10. Jakob C., Sterz J., Liebisch P., et al. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia 22 (2008) 1812
11. Lin P., Owens R., Tricot G., and Wilson C.S. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 121 (2004) 482-488
12. Mateo G., Montalban M.A., Vidriales M.B., et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 26 (2008) 2737-2744
13. Bergsagel P.L., Smith A.M., Szczepek A., Mant M.J., Belch A.R., and Pilarski L.M. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 85 (1995) 436-447
14. Szczepek A.J., Seeberger K., Wizniak J., Mant M.J., Belch A.R., and Pilarski L.M. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 92 (1998) 2844-2855
15. Wilson C.S., Butch A.W., Lai R., et al. Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy. Br J Haematol 112 (2001) 776-782
16. Hoyer J.D., Hanson C.A., Fonseca R., Greipp P.R., Dewald G.W., and Kurtin P.J. The (11;14) (q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol 113 (2000) 831-837
17. Chng W.J., Glebov O., Bergsagel P.L., and Kuehl W.M. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 20 (2007) 571-596
18. Li Z.W., Chen H., Campbell R.A., Bonavida B., and Berenson J.R. NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol 15 (2008) 391-399
19. Yasui H., Hideshima T., Richardson P.G., and Anderson K.C. Recent advances in the treatment of multiple myeloma. Curr Pharm Biotechnol 7 (2006) 381-393
20. Anargyrou K., Dimopoulos M.A., Sezer O., and Terpos E. Novel anti-myeloma agents and angiogenesis. Leuk Lymphoma 49 (2008) 677-689
21. Hideshima T., Raje N., Richardson P.G., and Anderson K.C. A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag 4 (2008) 129-136
22. Mateos M.V., and San Miguel J.F. Bortezomib in multiple myeloma. Best Pract Res Clin Haematol 20 (2007) 701-715
23. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol 23 (2005) 3412-3420
24. Chng W.J., Kuehl W.M., Bergsagel P.L., and Fonseca R. Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia 22 (2008) 459-461
25. Soutar R., Lucraft H., Jackson G., et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol 124 (2004) 717-726
26. Pellat-Deceunynck C., Barille S., Jego G., et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 12 (1998) 1977-1982
27. Tiedemann R.E., Gonzalez-Paz N., Kyle R.A., et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 22 (2008) 1044-1052
28. Rajkumar S.V., Lacy M.Q., and Kyle R.A. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev 21 (2007) 255-265
29. Kyle R.A., and Rajkumar S.V. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am 21 (2007) 1093-1113 ix
30. Kyle R.A., and Rajkumar S.V. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol 20 (2007) 637-664
31. Hardin J., Waddell M., Page C.D., et al. Evaluation of multiple models to distinguish closely related forms of disease using DNA microarray data: an application to multiple myeloma. Stat Appl Genet Mol Biol 3 (2004) Article 10
32. Gertz M.A., and Rajkumar S.V. Primary systemic amyloidosis. Curr Treat Options Oncol 3 (2002) 261-271
33. Rajkumar S.V., and Gertz M.A. Advances in the treatment of amyloidosis. N Engl J Med 356 (2007) 2413-2415
34. Gertz M.A., Lacy M.Q., Dispenzieri A., and Hayman S.R. Amyloidosis. Best Pract Res Clin Haematol 18 (2005) 709-727
35. Katzmann J.A., Abraham R.S., Dispenzieri A., Lust J.A., and Kyle R.A. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 51 (2005) 878-881
36. Buxbaum J., and Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am 13 (1999) 1235-1248
37. Gokden N., Barlogie B., and Liapis H. Morphologic heterogeneity of renal light-chain deposition disease. Ultrastruct Pathol 32 (2008) 17-24